title: Inhibition of the PLP-dependent enzyme serine palmitoyltransferase by cycloserine: evidence for a novel decarboxylative mechanism of inactivation.
abstract: Cycloserine (CS, 4-amino-3-isoxazolidone) is a cyclic amino acid mimic that is known to inhibit many essential pyridoxal 5'-phosphate (PLP)-dependent enzymes. Two CS enantiomers are known; D-cycloserine (DCS, also known as Seromycin) is a natural product that is used to treat resistant Mycobacterium tuberculosis infections as well as neurological disorders since it is a potent NMDA receptor agonist, and L-cycloserine (LCS) is a synthetic enantiomer whose usefulness as a drug has been hampered by its inherent toxicity arising through inhibition of sphingolipid metabolism. Previous studies on various PLP-dependent enzymes revealed a common mechanism of inhibition by both enantiomers of CS; the PLP cofactor is disabled by forming a stable 3-hydroxyisoxazole/pyridoxamine 5'-phosphate (PMP) adduct at the active site where the cycloserine ring remains intact. Here we describe a novel mechanism of CS inactivation of the PLP-dependent enzyme serine palmitoyltransferase (SPT) from Sphingomonas paucimobilis. SPT catalyses the condensation of l-serine and palmitoyl-CoA, the first step in the de novo sphingolipid biosynthetic pathway. We have used a range of kinetic, spectroscopic and structural techniques to postulate that both LCS and DCS inactivate SPT by transamination to form a free pyridoxamine 5'-phosphate (PMP) and beta-aminooxyacetaldehyde that remain bound at the active site. We suggest this occurs by ring opening of the cycloserine ring followed by decarboxylation. Enzyme kinetics show that inhibition is reversed by incubation with excess PLP and that LCS is a more effective SPT inhibitor than DCS. UV-visible spectroscopic data, combined with site-directed mutagenesis, suggest that a mobile Arg(378) residue is involved in cycloserine inactivation of SPT.
authors.affiliation: EaStChem, School of Chemistry, The University of Edinburgh, West Mains Road, Edinburgh, EH9 3JJ, Scotland, UK.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Lowther
authors.forename: Beverley A
authors.initials: BA
authors.lastname: Yard
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Johnson
authors.forename: Lester G
authors.initials: LG
authors.lastname: Carter
authors.forename: Venugopal T
authors.initials: VT
authors.lastname: Bhat
authors.forename: Marine C C
authors.initials: MC
authors.lastname: Raman
authors.forename: David J
authors.initials: DJ
authors.lastname: Clarke
authors.forename: Britta
authors.initials: B
authors.lastname: Ramakers
authors.forename: Stephen A
authors.initials: SA
authors.lastname: McMahon
authors.forename: James H
authors.initials: JH
authors.lastname: Naismith
authors.forename: Dominic J
authors.initials: DJ
authors.lastname: Campopiano
mesh_terms: D002853:Chromatography, Liquid; D003523:Cycloserine / Q000737:chemistry / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013058:Mass Spectrometry; D015394:Molecular Structure; D017433:Protein Structure, Secondary; D051102:Serine C-Palmitoyltransferase / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D020578:Sphingomonas / Q000201:enzymology
chemical_list: D004791:Enzyme Inhibitors; D003523:Cycloserine; D051102:Serine C-Palmitoyltransferase
references.citation: J Org Chem. 1971 Sep 10;36(18):2631-4
references.pmid: 5130583
references.citation: Biochemistry. 1964 Apr;3:471-80
references.pmid: 14188160
references.citation: Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
references.pmid: 15299926
references.citation: Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
references.pmid: 15272157
references.citation: Biochem Pharmacol. 1975 Jun 15;24(11-12):1153-60
references.pmid: 1137602
references.citation: Protein Sci. 2008 Jun;17(6):1066-76
references.pmid: 18434499
references.citation: Cancer Res. 2009 Dec 15;69(24):9457-64
references.pmid: 19934323
references.citation: Biochemistry. 2003 May 20;42(19):5775-83
references.pmid: 12741835
references.citation: J Biochem. 2009 Oct;146(4):549-62
references.pmid: 19564159
references.citation: J Mol Biol. 2007 Jul 27;370(5):870-86
references.pmid: 17559874
references.citation: Biochemistry. 2008 Jul 22;47(29):7734-43
references.pmid: 18570438
references.citation: J Neurochem. 1984 Feb;42(2):577-81
references.pmid: 6693888
references.citation: Biochem Pharmacol. 2000 May 15;59(10):1211-6
references.pmid: 10736421
references.citation: Acta Crystallogr D Biol Crystallogr. 2006 Apr;62(Pt 4):439-50
references.pmid: 16552146
references.citation: Biochemistry. 2004 Feb 3;43(4):1082-92
references.pmid: 14744154
references.citation: J Mol Biol. 2009 Sep 25;392(3):763-73
references.pmid: 19631226
references.citation: J Biol Chem. 1981 May 10;256(9):4263-8
references.pmid: 7217082
references.citation: Structure. 2002 Nov;10(11):1569-80
references.pmid: 12429098
references.citation: J Biol Chem. 1962 Oct;237:3245-9
references.pmid: 14033211
references.citation: J Biol Chem. 2004 Oct 29;279(44):46153-61
references.pmid: 15302886
references.citation: J Biol Chem. 2008 Mar 21;283(12):7542-53
references.pmid: 18167344
references.citation: J Lipid Res. 1965 Oct;6(4):537-44
references.pmid: 5865382
references.citation: Biochim Biophys Acta. 2003 Jun 10;1632(1-3):16-30
references.pmid: 12782147
references.citation: Biochemistry. 2000 Jan 25;39(3):516-28
references.pmid: 10642176
references.citation: Nat Chem Biol. 2007 Sep;3(9):565-9
references.pmid: 17676039
references.citation: Antimicrob Agents Chemother. 1984 Aug;26(2):211-3
references.pmid: 6486763
references.citation: J Biol Chem. 2008 Jun 27;283(26):18113-23
references.pmid: 18411263
references.citation: Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
references.pmid: 18216770
references.citation: J Lipid Res. 1985 Apr;26(4):473-7
references.pmid: 4009064
references.citation: Biochim Biophys Acta. 2009 Jul;1794(7):1030-40
references.pmid: 19328247
references.citation: Antibiot Chemother (Northfield). 1955 Apr;5(4):204-5
references.pmid: 24543467
references.citation: Proc Natl Acad Sci U S A. 2009 May 19;106(20):8186-91
references.pmid: 19416851
references.citation: Arch Microbiol. 1982 May;131(3):208-11
references.pmid: 7049104
references.citation: Nat Chem Biol. 2009 Dec;5(12):891-5
references.pmid: 19838203
references.citation: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
references.pmid: 15572765
references.citation: J Biol Chem. 2009 Jun 19;284(25):17328-17339
references.pmid: 19376777
references.citation: FEBS Lett. 2000 May 26;474(1):63-5
references.pmid: 10828452
references.citation: Antibiot Chemother (Northfield). 1955 Apr;5(4):183-90
references.pmid: 24543464
references.citation: J Lipid Res. 2008 Aug;49(8):1621-39
references.pmid: 18499644
references.citation: Bioorg Med Chem Lett. 2007 Mar 15;17(6):1651-4
references.pmid: 17267220
references.citation: J Antimicrob Chemother. 2004 Sep;54(3):593-602
references.pmid: 15282233
references.citation: Biochemistry. 2001 May 1;40(17):5151-60
references.pmid: 11318637
references.citation: Annu Rev Biochem. 2004;73:383-415
references.pmid: 15189147
references.citation: Pharmacol Res. 2008 Jul;58(1):45-51
references.pmid: 18611440
references.citation: FEBS J. 2008 Dec;275(23):5767-73
references.pmid: 19021754
references.citation: J Bioenerg Biomembr. 1995 Apr;27(2):151-9
references.pmid: 7592562
references.citation: J Biol Chem. 2002 Nov 22;277(47):44660-9
references.pmid: 12191993
references.citation: J Mol Biol. 1999 Nov 19;294(1):193-200
references.pmid: 10556038
references.citation: Neuropharmacology. 2001 Aug;41(2):151-8
references.pmid: 11489451
references.citation: EMBO Rep. 2004 Aug;5(8):777-82
references.pmid: 15289826
references.citation: Biochemistry. 2005 Apr 12;44(14):5317-27
references.pmid: 15807525
references.citation: Nature. 1997 Jun 5;387(6633):569-72
references.pmid: 9177342
references.citation: J Mol Biol. 1998 Nov 27;284(2):401-19
references.pmid: 9813126